Leqembi Receives Priority Review in China for Early Alzheimer’s Treatment

February 9, 2026 – Eisai, the Japanese pharmaceutical company and partner to BioArctic, has received priority review designation from the National Medical Products Administration (NMPA) in China for its application to market a subcutaneous formulation of Leqembi (lecanemab) for the treatment of early Alzheimer’s disease. This expedited review process signals the NMPA’s recognition of the potential significance of Leqembi in addressing a growing public health challenge in China.

The application submitted to the NMPA covers a formulation designed for subcutaneous administration via an autoinjector, offering a potentially more convenient method of delivery compared to the current intravenous infusion required for Leqembi. The NMPA accepted the application for review in January 2026, and the priority review designation further accelerates the evaluation process.

Leqembi, developed by Eisai and co-discovered with BioArctic, is a monoclonal antibody designed to target and remove amyloid plaques, a hallmark of Alzheimer’s disease. It represents a novel approach to treating the underlying pathology of the disease, rather than merely managing symptoms. The drug received accelerated approval in the United States in July 2023, and full approval in January 2024, marking a significant milestone in Alzheimer’s research and treatment.

The Chinese market represents a substantial opportunity for Leqembi, given China’s large and rapidly aging population. Alzheimer’s disease is becoming increasingly prevalent in China, placing a growing burden on healthcare systems and families. The availability of a disease-modifying treatment like Leqembi could significantly improve the quality of life for patients and reduce the long-term costs associated with Alzheimer’s care.

The priority review designation in China does not guarantee approval, but it does indicate that the NMPA will dedicate additional resources to expedite the review process. This typically shortens the timeframe for a decision, potentially allowing Leqembi to reach Chinese patients more quickly. The subcutaneous formulation, if approved, is expected to enhance patient convenience and adherence to treatment.

BioArctic, the Swedish biotechnology company, stands to benefit financially from the potential success of Leqembi in China. As Eisai’s partner, BioArctic receives royalties on sales of the drug globally. The Chinese market is expected to become a major contributor to Leqembi’s overall revenue, bolstering BioArctic’s financial performance.

The development of Leqembi and its progression through regulatory approvals worldwide highlight a growing global focus on addressing Alzheimer’s disease. While existing treatments primarily focus on symptom management, Leqembi’s mechanism of action – targeting amyloid plaques – represents a shift towards disease modification. This approach has garnered significant attention from the medical community and investors alike.

The recent receipt of the Prime Minister’s Award at the 12th Technology Management and Innovation Awards in Japan further underscores the significance of Leqembi’s development. This recognition highlights the innovative nature of the drug and its potential to transform the treatment of Alzheimer’s disease.

The approval of a weekly at-home injection formulation of Leqembi, as indicated by recent FDA action, further expands the accessibility and convenience of the treatment. This development, coupled with the priority review in China, positions Leqembi as a leading contender in the evolving Alzheimer’s disease treatment landscape.

Investors are closely monitoring the progress of Leqembi in key markets, including China. The potential for substantial revenue growth in China, combined with the convenience of the subcutaneous formulation, could drive further appreciation in the stock prices of both Eisai and BioArctic. However, the pharmaceutical industry is subject to regulatory risks and competitive pressures, and the ultimate success of Leqembi will depend on a variety of factors, including clinical outcomes, market acceptance, and pricing strategies.

The NMPA’s decision on the Leqembi application is anticipated in the coming months. The outcome will have significant implications for patients with early Alzheimer’s disease in China, as well as for the financial prospects of Eisai and BioArctic. The ongoing development and global rollout of Leqembi represent a pivotal moment in the fight against Alzheimer’s disease, offering hope for a more effective treatment of this devastating condition.